Thermo Fisher Scientific Europe — Consolidated revenues increased by 11.9% to $3.01B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 11.9%, from $2.69B to $3.01B. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates growing market share or rising demand for scientific and laboratory solutions in Europe, while a decrease may signal regional economic headwinds or increased competitive pressure.
This metric represents the total gross revenue generated by the company's operations within the European geographic regi...
Peers in the life sciences and diagnostics industry typically report regional revenues to highlight geographic diversification and exposure to specific healthcare regulatory environments.
tmo_segment_europe_consolidated_revenues| Q2 '21 | Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q3 '24 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $2.70B | $3.05B | $2.55B | $2.69B | $2.69B | $2.69B | $2.69B | $2.69B | $3.01B |
| QoQ Change | — | +13.2% | -16.4% | +5.3% | +0.0% | +0.0% | +0.0% | +0.0% | +11.9% |
| YoY Change | — | — | -5.3% | -12.0% | +5.3% | — | — | +0.0% | +11.9% |
We use cookies for analytics. See our Privacy and Cookie Policy.